{"organizations": [], "uuid": "25e8eaf209efc121a0d4e2e9e230bc157dcfd600", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-jazz-pharma-submits-supplemental-n/brief-jazz-pharma-submits-supplemental-new-drug-application-for-xyrem-to-treat-cataplexy-and-excessive-daytime-sleepiness-in-pediatric-narcolepsy-patients-idUSFWN1S807Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Jazz Pharma Submits Supplemental New Drug Application For Xyrem To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T15:56:00.000+03:00", "replies_count": 0, "uuid": "25e8eaf209efc121a0d4e2e9e230bc157dcfd600"}, "author": "", "url": "https://www.reuters.com/article/brief-jazz-pharma-submits-supplemental-n/brief-jazz-pharma-submits-supplemental-new-drug-application-for-xyrem-to-treat-cataplexy-and-excessive-daytime-sleepiness-in-pediatric-narcolepsy-patients-idUSFWN1S807Z", "ord_in_thread": 0, "title": "BRIEF-Jazz Pharma Submits Supplemental New Drug Application For Xyrem To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-jazz pharma", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "pediatric narcolepsy patients reuters", "sentiment": "none"}, {"name": "jazz pharmaceuticals plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News May 1, 2018 / 12:56 PM / Updated 5 minutes ago BRIEF-Jazz Pharma Submits Supplemental New Drug Application For Xyrem To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients Reuters Staff 1 Min Read\nMay 1 (Reuters) - Jazz Pharmaceuticals PLC:\n* JAZZ PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR XYREMÂ® (SODIUM OXYBATE) TO TREAT CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T15:56:00.000+03:00", "crawled": "2018-05-01T16:05:22.006+03:00", "highlightTitle": ""}